Pacira Pharma phase 4 study of Exparel in patients undergoing Csection achieves primary endpoint with significant reductions in opioid consumption

Pacira Pharma phase 4 study of Exparel in patients undergoing C─section achieves primary endpoint with significant reductions in opioid consumption

Pacira Pharmaceuticals, announced that its phase 4 study of Exparel (bupivacaine liposome injectable suspension) in patients undergoing Cesarean section (C─section) achieved its primary endpoint with a

More From BioPortfolio on "Pacira Pharma phase 4 study of Exparel in patients undergoing C─section achieves primary endpoint with significant reductions in opioid consumption"